Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer

Phase 3

Active, not recruiting

• Conditions: Colorectal Cancer Metastatic
• Interventions: Biological: FOLFIRI-cetuximab; Biological: OPTIMOX-bevacizumab; Biological: mFOLFOX6-bevacizumab; Biological: irinotecan-based chemo + bevacizumab; Biological: Anti-EGFR agent (cetuximab +/- irinotecan or panitumumab); Biological: XELOX + bevacizumab

• Registration Number: NCT01910610
• Lead Sponsor: GERCOR - Multidisciplinary Oncology Cooperative Group

Brief Summary

STRATEGIC-1 is a study designed to determine the best sequence of therapy in patients with metastatic colorectal cancer.

Detailed Description

This is a phase III study assessing 2 mutli-line therapeutic strategies in patients with unresectable wild-type RAS metastatic colorectal cancer. All the available treatments are being used in each strategy (oxaliplatine, irinotecan, fluoropyrimidines, bevacizumab, cetuximab or panitumumab) but in a different order:

STRATEGY A: FOLFIRI-cetuximab, followed by oxaliplatin-based chemotherapy with bevacizumab vs.

STRATEGY B: OPTIMOX-bevacizumab, followed by irinotecan-based chemotherapy with bevacizumab, followed by anti-EGFR mab with or without irinotecan.

Study Timeline

• Study First Submitted: 2013-07-23
• Study First Submitted QC: 2013-07-25
• Study First Posted: 2013-07-29
• Study Start: 2013-10-30
• Primary Completion: 2023-07-13
• Status Verified: 2024-03
• Last Update Submitted: 2024-03-08
• Last Update Posted: 2024-03-12
• Study Completion: 2024-12

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 464

Inclusion Criteria

1. Signed and dated informed consent, and willing and able to comply with protocol requirements,
2. Histologically proven adenocarcinoma of the colon and/or rectum,
3. Wild-type RAS tumor no mutation in exon 2 [codon 12/13], exon 3 [codon 59/61] and exon 4 [codon 117/146] of both KRAS and NRAS genes (local assessment, performed either on primary tumor or metastasis), In exceptional circumstances, RAS mutational status (KRAS and NRAS) can be pending at time of randomization, provided it is obtained within the first two cycles of first line therapy
4. Metastatic disease confirmed,
5. No prior therapy for metastatic disease (in case of previous adjuvant therapy, interval from end of chemotherapy and relapse must be >6 months for fluoropyrimidine alone or >12 months for oxaliplatin-based, bevacizumab-based, or cetuximab-based therapy),
6. Duly documented unresectable metastatic disease, ie not suitable for complete carcinological surgical resection at inclusion [NB: patients with unresectable disease at study entry but with any potential of salvage surgery after induction therapy are eligible],
7. At least one measurable or evaluable lesion as assessed by CT-scan or MRI (Magnetic Resonance Imaging) according to RECIST v1.1,
8. Age ≥18 years,
9. ECOG Performance status (PS) 0-2,
10. Hematological status: neutrophils (ANC) ≥1.5x109/L; platelets ≥100x109/L; haemoglobin ≥9g/dL,
11. Adequate renal function: serum creatinine level <150µM,
12. Adequate liver function: serum bilirubin ≤1.5 x upper normal limit (ULN), alkaline phosphatase <5xULN,
13. Proteinuria <2+ (dipstick urinalysis) or ≤1g/24hour,
14. Baseline evaluations performed before randomization when the KRAS WT status is known: clinical and blood evaluations no more than 2 weeks (14 days) prior to randomization, tumor assessment (CT-scan or MRI, evaluation of non-measurable lesions) no more than 3 weeks (21 days) prior to randomization,
15. Female patients must commit to using reliable and appropriate methods of contraception during the trial and until at least six months after the end of study treatment (when applicable). Male patients with a partner of childbearing potential must agree to use contraception in addition to having their partner use another contraceptive method during the trial and until at least 6 months after the end of the study treatment,
16. Registration in a national health care system (CMU included for France).

Exclusion Criteria

1. History or evidence upon physical examination of CNS metastasis (e.g. non irradiated CNS metastasis, seizure not controlled with standard medical therapy), unless adequately treated,
2. Exclusive bone metastasis,
3. Uncontrolled hypercalcemia,
4. Pre-existing permanent neuropathy (NCI grade ≥2),
5. Uncontrolled hypertension (defined as systolic blood pressure >150 mmHg and/or diastolic blood pressure >100 mmHg), or history of hypertensive crisis, or hypertensive encephalopathy,
6. Concomitant unplanned antitumor therapy (e.g. chemotherapy, molecular targeted therapy, immunotherapy),
7. Treatment with any investigational medicinal product within 28 days prior to study entry,
8. Other serious and uncontrolled non-malignant disease,
9. Gilbert's syndrome,
10. Other concomitant or previous malignancy, except: i/ adequately treated in-situ carcinoma of the uterine cervix, ii/ basal or squamous cell carcinoma of the skin, iii/ cancer in complete remission for >5 years,
11. Major surgery (open biopsy, surgical resection, wound revision or any other major surgery involving entry into body cavity) or significant traumatic injury within the last 28 days prior to randomization, and/or minor surgical procedure including placement of a vascular device within 2 days of first study treatment,
12. Pregnant or breastfeeding women,
13. Patients with known allergy/hypersensitivity to any component of study drugs,
14. History of arterial thrombo and/or embolic event (e.g. myocardial infarction, stroke,...) within 6 months prior to randomization,
15. Chronic inflammatory bowel disease
16. Total bowel obstruction,
17. History of abdominal fistula, GI perforation, intra-abdominal abscess or active GI bleeding within 6 months prior to randomization,
18. Serious, non-healing wound, active ulcer or untreated bone fracture,
19. History or evidence of inherited bleeding diathesis or significant coagulopathy at risk of bleeding,
20. Current or recent (within 10 days of randomization) use of aspirin (>325 mg/d), clopidogrel (>75 mg/d) or use of oral anticoagulants or thrombolytic agents.
21. Concomitant administration of live, attenuated virus vaccine such as yellow fever vaccine
22. Concomitant administration of prophylactic phenytoin.
23. Treatment with sorivudine or its chemically related analogues, such as brivudine.
24. Patients with known dihydropyrimidine dehydrogenase (DPD) deficiency.
25. Concomitant use with St John's Wort
26. Patients with interstitial pneumonitis or pulmonary fibrosis

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
STRATEGY A	mFOLFOX6-bevacizumab	FOLFIRI-cetuximab, followed by oxaliplatin-based chemotherapy with bevacizumab
STRATEGY B	irinotecan-based chemo + bevacizumab	OPTIMOX-bevacizumab, followed by irinotecan-based chemotherapy with bevacizumab, followed by anti-EGFR mab with or without irinotecan
STRATEGY A	FOLFIRI-cetuximab	FOLFIRI-cetuximab, followed by oxaliplatin-based chemotherapy with bevacizumab
STRATEGY B	XELOX + bevacizumab	OPTIMOX-bevacizumab, followed by irinotecan-based chemotherapy with bevacizumab, followed by anti-EGFR mab with or without irinotecan
STRATEGY A	XELOX + bevacizumab	FOLFIRI-cetuximab, followed by oxaliplatin-based chemotherapy with bevacizumab
STRATEGY B	OPTIMOX-bevacizumab	OPTIMOX-bevacizumab, followed by irinotecan-based chemotherapy with bevacizumab, followed by anti-EGFR mab with or without irinotecan
STRATEGY B	Anti-EGFR agent (cetuximab +/- irinotecan or panitumumab)	OPTIMOX-bevacizumab, followed by irinotecan-based chemotherapy with bevacizumab, followed by anti-EGFR mab with or without irinotecan

Primary Outcome Measures

Name	Time	Method
Duration of Disease Control (DDC)	From baseline until end of strategy; up to 80 months after the beginning of the study	DDC is defined as the sum of PFS of each active treatment course planned in the treatment strategy. DDC excludes 1) intervals between disease progression and re-initiation of treatment, and 2) PFS of inactive treatment if PD occurs at first evaluation after treatment re-initiation (either reintroduction in a stop-and-go strategy or subsequent course of treatment in a multi-line strategy).

Secondary Outcome Measures

Name	Time	Method
Assessment of Quality of life (QoL)	From baseline until end of strategy; up to 80 months after the beginning of the study	QoL will be considered to be improved if at least one time to QoL score deterioration (5 targeted dimensions) will be significantly longer without a significant shorter time to QoL score dimensions for other 4 targeted dimensions.
Tumor Response Rate (RR)	From baseline until end of strategy; up to 80 months after the beginning of the study	Tumor response will be assessed using RECIST version 1.1 per sequence of therapy
Overall Survival (OS)	Up to 80 months after the beginning of the study	Time from randomization to the date of death from any cause
Progression-free survival (PFS) per sequence of therapy	Up to 80 months after the beginning of the study	Time from randomization to the date of first documented disease progression or death from any cause, whichever occurs first.
Curative salvage surgery rate	From baseline until end of strategy; up to 80 months after the beginning of the study	The number of patient with R0 and R1 curative salvage surgery will be assessed globally (per arm) and per sequence of therapy
Safety profile of each treatment sequence	From study entry to 1 month after last study drug administration; up to 80 months after the beginning of the study	The report will take into account all adverse events observed during and after drug administration, including any adverse events that may be related to the administration procedure itself.
Time to Failure of Strategy (TFS)	Up to 80 months after the beginning of the study	TFS is defined as beginning with the initiation of the strategy under investigation and ending with the first of the following events: 1) death, 2) disease progression on the last received planned sequence, 3) patient requires the addition of a new (unplanned) therapeutic agent, 4) patient experiences disease progression during a partial or complete break in therapy from initial treatment strategy and receives no further therapy within one month.

Trial Locations

Locations (55)

Clinique Générale; 🇫🇷 Valence, France

Centre Hospitalier; 🇫🇷 Dax, France

St. James's Hospital; 🇮🇪 Dublin, Ireland

St. Vincent's University Hospital; 🇮🇪 Dublin, Ireland

Centre hospitalier Auxerre; 🇫🇷 Auxerre, France

Centre François Baclesse; 🇫🇷 Caen, France

Hôpital Henri Mondor; 🇫🇷 Créteil, France

Centre d'oncologie et de radiothérapie du Parc; 🇫🇷 Dijon, France

Centre Georges François Leclerc; 🇫🇷 Dijon, France

CHD Vendée; 🇫🇷 La Roche sur Yon, France

Hôpital Privé de l'Estuaire; 🇫🇷 Le Havre, France

Clinique Victor Hugo; 🇫🇷 Le Mans, France

Institut d'oncoloige Hartmann; 🇫🇷 Levallois Perret, France

Institut Hospitalier Franco-Britannique; 🇫🇷 Levallois Perret, France

Centre Bourgogne; 🇫🇷 Lille, France

Hôpital Nord; 🇫🇷 Marseille, France

Centre Sainte Catherine de Sienne; 🇫🇷 Nantes, France

Hôpital Tenon; 🇫🇷 Paris, France

Institut Mutualiste Montsouris; 🇫🇷 Paris, France

Hôpital Broussais - CH Saint Malo; 🇫🇷 Saint Malo, France

CH de Senlis; 🇫🇷 Senlis, France

Hôpital Foch; 🇫🇷 Suresnes, France

Hôpitaux du Léman; 🇫🇷 Thonon Les Bains, France

Hôpital Sainte Musse; 🇫🇷 Toulon, France

Adelaide & Meath Hospital Dublin ( AMNCH); 🇮🇪 Dublin, Ireland

Mater Misericordiae University Hospital; 🇮🇪 Dublin, Ireland

Centre Hospitalier Annecy Gennevois; 🇫🇷 Annecy, France

Centre Hospitalier Chateauroux; 🇫🇷 Chateauroux, France

Hospices Civils de Colmar; 🇫🇷 Colmar, France

Hôpital Européen; 🇫🇷 Marseille, France

Centre d'oncologie de Gentilly; 🇫🇷 Nancy, France

Centre Hospitalier de Sens; 🇫🇷 Sens, France

Sheba Tel Hashomer; 🇮🇱 Ramat Gan, Israel

Hôpital Louis Pasteur; 🇫🇷 Le Coudray, France

Institut de Cancérologie; 🇫🇷 Villeneuve-d'Ascq, France

University Hospital Galway; 🇮🇪 Galway, Ireland

Assaf Harofeh Medical Center; 🇮🇱 Zerifin, Israel

Hôpital Privé Jean Mermoz; 🇫🇷 Lyon, France

Hôpital Saint-Louis; 🇫🇷 Paris, France

Centre Hospitalier de Bretagne Sud; 🇫🇷 Lorient, France

Bon Secours Hospital; 🇮🇪 Cork, Ireland

Cork University Hospital; 🇮🇪 Cork, Ireland

Hôpital Saint-Antoine; 🇫🇷 Paris, France

Hôpital Périgueux; 🇫🇷 Périgueux, France

University Hospital Waterford; 🇮🇪 Waterford, Ireland

Centre Hospitalier Layné; 🇫🇷 Mont de Marsan, France

Clinique de l'Alliance; 🇫🇷 Saint Cyr sur Loire, France

Institut de Cancérologie Lucien Neuwirth; 🇫🇷 Saint Priest en Jarez, France

Clinique Armoricaine de Radiologie; 🇫🇷 Saint-Brieuc, France

Clinique Sainte-Anne; 🇫🇷 Strasbourg, France

Beaumont Hospital; 🇮🇪 Dublin, Ireland

Mater Private Hospital; 🇮🇪 Dublin, Ireland

Hôpital Cochin; 🇫🇷 Paris, France

Hôpital Pitié-Salpêtrière; 🇫🇷 Paris, France

Hôpital Saint-Joseph; 🇫🇷 Paris, France